Screening Methods for Age-Related Hearing Loss in Older Patients with Cancer: A Review of the Literature

Lycke, Michelle; Lefebvre, Tessa; Cool, Lieselot; Eygen, Koen Van; Boterberg, Tom; Schofield, Patricia; Debruyne, Philip R.

doi:10.3390/geriatrics3030048

Cited by 4 publications

(3 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The tested frequency range of 4–16 kHz in mice corresponds approximately to the 1–4 kHz range in human beings [ 39 ]. This range is essential for normal speech perception and regularly tested during basic audiologic assessments [ 79 , 80 , 81 , 82 , 83 ], and also used in guidelines recommending the sound pressure level of hearing impairment that is required for prescribing hearing aids [ 84 ]. This matching in the practically relevant mouse-human frequency range provides a reliable translational value to our study.…”

Section: Methodsmentioning

confidence: 99%

Chronic Oral Selegiline Treatment Mitigates Age-Related Hearing Loss in BALB/c Mice

Szepesy

Humli

Farkas

et al. 2021

IJMS

View full text Add to dashboard Cite

Age-related hearing loss (ARHL), a sensorineural hearing loss of multifactorial origin, increases its prevalence in aging societies. Besides hearing aids and cochlear implants, there is no FDA approved efficient pharmacotherapy to either cure or prevent ARHL. We hypothesized that selegiline, an antiparkinsonian drug, could be a promising candidate for the treatment due to its complex neuroprotective, antioxidant, antiapoptotic, and dopaminergic neurotransmission enhancing effects. We monitored by repeated Auditory Brainstem Response (ABR) measurements the effect of chronic per os selegiline administration on the hearing function in BALB/c and DBA/2J mice, which strains exhibit moderate and rapid progressive high frequency hearing loss, respectively. The treatments were started at 1 month of age and lasted until almost a year and 5 months of age, respectively. In BALB/c mice, 4 mg/kg selegiline significantly mitigated the progression of ARHL at higher frequencies. Used in a wide dose range (0.15–45 mg/kg), selegiline had no effect in DBA/2J mice. Our results suggest that selegiline can partially preserve the hearing in certain forms of ARHL by alleviating its development. It might also be otoprotective in other mammals or humans.

show abstract

Section: Methodsmentioning

confidence: 99%

Chronic Oral Selegiline Treatment Mitigates Age-Related Hearing Loss in BALB/c Mice

Szepesy

Humli

Farkas

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“… Alcohol consumption - Quantity-frequency measures with beverage-specific assessment of time frames and binge-drinking episodes [ 37 ] ( ideal ) - > 21 units per week to define high risk ( more practical ) Obesity and visceral adipose tissue - Waist circumference ( ideal ) - Body mass index ( practical ) Note : There are different ways to measure waist circumference and different cut-offs depending on ethnicity and world region [ 38 ]. Hearing impairment - Pure tone audiometry [ 39 ] ( gold standard ) - Whispered Voice Test ( simple but less reliable ) - Speech-in-noise paradigms ( simple but less reliable ) - Questionnaires ( less reliable ) Diabetes - Fasting plasma glucose levels (> = 7.0 mmol/l) or HbA1c (> = 6.5%) - Oral glucose tolerance test to diagnose impaired glucose tolerance [ 40 ]. Smoking - Pack years (number of daily packs multiplied by number of years smoking) - Current smoking status (current versus former/never smoker) Air pollution - Further research is needed to establish a practical clinically relevant measure.…”

Section: Assessments In the Clinicmentioning

confidence: 99%

Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services—part 2 of 6

et al. 2021

View full text Add to dashboard Cite

We envisage the development of new Brain Health Services to achieve primary and secondary dementia prevention. These services will complement existing memory clinics by targeting cognitively unimpaired individuals, where the focus is on risk profiling and personalized risk reduction interventions rather than diagnosing and treating late-stage disease. In this article, we review key potentially modifiable risk factors and genetic risk factors and discuss assessment of risk factors as well as additional fluid and imaging biomarkers that may enhance risk profiling. We then outline multidomain measures and risk profiling and provide practical guidelines for Brain Health Services, with consideration of outstanding uncertainties and challenges. Users of Brain Health Services should undergo risk profiling tailored to their age, level of risk, and availability of local resources. Initial risk assessment should incorporate a multidomain risk profiling measure. For users aged 39–64, we recommend the Cardiovascular Risk Factors, Aging, and Incidence of Dementia (CAIDE) Dementia Risk Score, whereas for users aged 65 and older, we recommend the Brief Dementia Screening Indicator (BDSI) and the Australian National University Alzheimer’s Disease Risk Index (ANU-ADRI). The initial assessment should also include potentially modifiable risk factors including sociodemographic, lifestyle, and health factors. If resources allow, apolipoprotein E ɛ4 status testing and structural magnetic resonance imaging should be conducted. If this initial assessment indicates a low dementia risk, then low intensity interventions can be implemented. If the user has a high dementia risk, additional investigations should be considered if local resources allow. Common variant polygenic risk of late-onset AD can be tested in middle-aged or older adults. Rare variants should only be investigated in users with a family history of early-onset dementia in a first degree relative. Advanced imaging with 18-fluorodeoxyglucose positron emission tomography (FDG-PET) or amyloid PET may be informative in high risk users to clarify the nature and burden of their underlying pathologies. Cerebrospinal fluid biomarkers are not recommended for this setting, and blood-based biomarkers need further validation before clinical use. As new technologies become available, advances in artificial intelligence are likely to improve our ability to combine diverse data to further enhance risk profiling. Ultimately, Brain Health Services have the potential to reduce the future burden of dementia through risk profiling, risk communication, personalized risk reduction, and cognitive enhancement interventions.

show abstract

“…Furthermore, glasses and hearing aids serve as corrective devices, so the sensory impairment indicator may not have high validity. Using more objective, biological measures or screening questionnaires (e.g., visual acuity test, pure tone audiometry, Hearing Handicap Inventory for Elderly) instead of selfreported measures would be beneficial (Gerstorf et al, 2013, Lycke et al, 2018.…”

Section: Limitations and Future Directionsmentioning

confidence: 99%

Toward a multidimensional understanding of later life disability: A latent profile analysis

Peterson¹

View full text Add to dashboard Cite

Screening Methods for Age-Related Hearing Loss in Older Patients with Cancer: A Review of the Literature

Cited by 4 publications

References 55 publications

Chronic Oral Selegiline Treatment Mitigates Age-Related Hearing Loss in BALB/c Mice

Chronic Oral Selegiline Treatment Mitigates Age-Related Hearing Loss in BALB/c Mice

Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services—part 2 of 6

Toward a multidimensional understanding of later life disability: A latent profile analysis

Contact Info

Product

Resources

About